CTKB vs. LAB, EYPT, QTRX, PACB, VALN, PRTA, ALLO, NAUT, MYGN, and OLK
Should you be buying Cytek Biosciences stock or one of its competitors? The main competitors of Cytek Biosciences include Standard BioTools (LAB), EyePoint Pharmaceuticals (EYPT), Quanterix (QTRX), Pacific Biosciences of California (PACB), Valneva (VALN), Prothena (PRTA), Allogene Therapeutics (ALLO), Nautilus Biotechnology (NAUT), Myriad Genetics (MYGN), and Olink Holding AB (publ) (OLK). These companies are all part of the "medical" sector.
Standard BioTools (NASDAQ:LAB) and Cytek Biosciences (NASDAQ:CTKB) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, community ranking, valuation, institutional ownership, dividends, media sentiment, profitability, earnings and risk.
Standard BioTools has a beta of 1.64, meaning that its share price is 64% more volatile than the S&P 500. Comparatively, Cytek Biosciences has a beta of 1.38, meaning that its share price is 38% more volatile than the S&P 500.
53.7% of Standard BioTools shares are held by institutional investors. Comparatively, 69.5% of Cytek Biosciences shares are held by institutional investors. 53.1% of Standard BioTools shares are held by company insiders. Comparatively, 15.9% of Cytek Biosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
In the previous week, Cytek Biosciences had 7 more articles in the media than Standard BioTools. MarketBeat recorded 8 mentions for Cytek Biosciences and 1 mentions for Standard BioTools. Standard BioTools' average media sentiment score of -0.02 beat Cytek Biosciences' score of -0.37 indicating that Cytek Biosciences is being referred to more favorably in the news media.
Cytek Biosciences has a net margin of -5.73% compared to Cytek Biosciences' net margin of -70.98%. Standard BioTools' return on equity of -1.78% beat Cytek Biosciences' return on equity.
Cytek Biosciences has higher revenue and earnings than Standard BioTools. Cytek Biosciences is trading at a lower price-to-earnings ratio than Standard BioTools, indicating that it is currently the more affordable of the two stocks.
Cytek Biosciences received 15 more outperform votes than Standard BioTools when rated by MarketBeat users. However, 100.00% of users gave Standard BioTools an outperform vote while only 42.86% of users gave Cytek Biosciences an outperform vote.
Standard BioTools currently has a consensus price target of $3.58, suggesting a potential upside of 43.33%. Cytek Biosciences has a consensus price target of $8.63, suggesting a potential upside of 39.56%. Given Cytek Biosciences' stronger consensus rating and higher possible upside, equities research analysts clearly believe Standard BioTools is more favorable than Cytek Biosciences.
Summary
Cytek Biosciences beats Standard BioTools on 10 of the 17 factors compared between the two stocks.
Get Cytek Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for CTKB and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CTKB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cytek Biosciences Competitors List
Related Companies and Tools
